Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 8Uterine Cervical Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumor, Pleural 1Rectal Neoplasms 1Neuroblastoma 1Muscle-invasive Bladder Cancer 1Mouth Neoplasms 1Mesothelioma, Malignant 1Melanoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Brain Neoplasms 1Body Weight Changes 1Anorexia 1Adenocarcinoma, Bronchiolo-Alveolar 1

Interventions

tremelimumab 1pembrolizumab 1enfortumab vedotin 1durvalumab 1Watchful Waiting 1Radiotherapy 1Palliative Care 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Muscle-invasive Bladder Cancer × Watchful Waiting × Clear all
NCT06686381 2025-02-05

Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W

American University of Beirut Medical Center

Phase 2 Not yet recruiting
80 enrolled
Genitourinary

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡